Immune intervention with glutamic acid decarboxylase (GAD) treatment of children and adolescents with recent onset of type 1 diabetes (T1D) seemed to delay the loss of endogenous C-peptide, at least in a phase II trial, and in some prespecified subgroups of a phase III trial 1,2. This evidence concerns the gene GAD1 and type 1 diabetes mellitus.